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The MUC1 glycoprotein is a major tumor associated anti-
gen in human epithelial cancers in which it is overex-
pressed and hypoglycosylated, in contrast to the heavily
glycosylated form of MUC1 found at lower expression
level in normal cells. The TG4010 immunotherapeutic
product consists of a suspension of attenuated vaccinia
virus (Ankara strain), genetically modified to express
MUC1 and the cytokine IL-2. The TG4010 immunothera-
peutic agent is currently in advanced clinical development
for non-small-cell lung cancer (NSCLC) in combination
with chemotherapy. Antigen-specific models were gener-
ated by transfecting murine tumor cell lines with the
human MUC1 and were used to address in vitro and in
vivo issues regarding the combinatorial approach of che-
motherapy and immunization with MVATG9931, an iso-
genic construct of TG4010. First, in vitro sensitivity to
drugs used as standard of care to treat advanced NSCLC
patients of the lymphoma RMA cell line and of the Lewis
Lung Carcinoma cell line (LLC) expressing, or not,
MUC1, was determined. The parental or transfected cell
lines had similar sensitivity to gemcitabine, pemetrexed or
the combination of these drugs with cisplatin. The in vivo
anti-tumoral activity of chemotherapy was assessed in syn-
geneic C57BL/6 mice bearing tumors. In contrast to the
in vitro situation, in vivo anti-tumoral activity of che-
motherapy was clearly superior in the RMA or LLC
MUC1-transfectants as compared to their respective un-
transfected counterpart. Further investigations of the LLC
model in vivo showed that MUC1 expression was linked
to increased tumor aggressiveness when compared to the
un-transfected LLC tumor with faster tumor growth and
increased splenomegaly. Analysis of inflammatory cells
and notably myeloid-derived suppressor cells (MDSC)
indicated that their proportion was increased in the blood,
spleen and tumor in mice bearing LLCMUC1 tumors as
compared to that of mice with LLC tumors. Finally, using
a gemcitabine-based regimen known to affect MDSC
viability, combination therapy of LLCMUC1 tumors with
MVATG9931 immunizations and gemcitabine/cisplatin
increased significantly mice survival as compared to that
of mice treated with chemotherapy alone. These preclini-
cal data argues for a strong rationale to combine TG4010
with chemotherapy in advanced NSCLC patients.
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